Twice-yearly depemokimab was associated with improvements in asthma symptoms, activity, and daily-life impact by week 4, with benefits sustained through 52 weeks in an analysis of 559 patients from the …
-
A study in JAMA Network Open found undeclared clobetasol propionate in 6 of 18 selected online skin products, raising concerns about hidden prescription drugs and consumer safety.
-
The FDA approved a once-daily Zilbrysq autoinjector for eligible adults with generalized myasthenia gravis, offering an alternative to the prefilled syringe. Early studies reported bioequivalence and generally favorable device tolerability.
- GastroenterologyNEWS/RESEARCHTRIALS
Subcutaneous Infliximab After a Drug Holiday in IBD: Study Findings
Subcutaneous infliximab helped patients with Crohnโs disease and ulcerative colitis regain or maintain disease control after an IV treatment interruption, with favorable outcomes reported regardless of antidrug antibody status.
-
The FDA approved Brytly, a nonprescription apraclonidine 0.125% eye drop for redness relief in people aged 12 years and older. Learn about dosing and use precautions.
- FDA & REGULATORY NEWSHematologyONCOLOGYUrology
FDA Expands Anktiva Approval for BCG-Unresponsive Bladder Cancer
The FDA expanded Anktiva plus BCG for adults with BCG-unresponsive, high-grade papillary-only nonโmuscle-invasive bladder cancer, adding a specifically approved treatment option for this subgroup.
-
A 29-year cohort analysis of 3,466 adults with MASLD found that body roundness index was more strongly associated with long-term mortality than BMI, including among lean and nonobese individuals.
NEWS/RESEARCHOphthalmologyPEDIATRICS
Essilor Stellest 2.0 Shows Early Myopia-Control Benefits in Children
Children wearing Essilor Stellest 2.0 lenses had less myopia progression and axial elongation after 6 months in interim trial results. Separate 2-year data support the original Stellest lens.
Anti-VEGF injections within 35 days before cataract surgery were associated with less postoperative macular edema in patients with retinal vein occlusion, according to a small retrospective study.
A retrospective study of 401 fracture-related infection cases found that fracture-specific consensus criteria identified more cases than CDC surgical site infection definitions, particularly beyond 90 days after surgery.
Newer Posts